8-K: Apyx Medical Appoints Stavros Vizirgianakis as New Chairman Following Andrew Makrides' Retirement

Apyx Medical Corporation announced the retirement of its Chairman, Andrew Makrides, and the appointment of Stavros Vizirgianakis as his successor, effective May 7, 2024.

Summary

• Apyx Medical Corporation has appointed Stavros G. Vizirgianakis as the new Chairman of the Board, effective May 7, 2024.
• This appointment follows the retirement of Andrew Makrides, who served as Chairman since 1982.
• Mr. Vizirgianakis will serve on the same basis as other non-employee directors and receive the same compensation and benefits.
• A letter agreement outlines the terms of Mr. Vizirgianakis's appointment, including a standstill agreement and cooperation on identifying an additional director.
• The company will nominate Mr. Vizirgianakis for reelection at the 2024 Annual Meeting of Stockholders.
• Mr. Vizirgianakis has extensive experience in the medical device industry, including previous CEO and board positions at other medical device companies.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the smooth leadership transition and the appointment of an experienced chairman. The language used is optimistic about the company's future prospects.

Positives

• The appointment of Stavros G. Vizirgianakis brings significant medical device industry experience to the board.
• The agreement ensures a smooth transition of leadership at the board level.
• The standstill agreement provides stability and prevents potential disruptions from the new chairman.
• The company is actively working to identify an additional independent director to further strengthen the board.

Negatives

• The departure of Andrew Makrides marks the end of a long tenure of leadership at the company.
• The standstill agreement restricts Mr. Vizirgianakis's actions as a stockholder, which could limit his influence.

Risks

• The inability to identify a mutually acceptable additional director within nine months could lead to delays in board expansion.
• The standstill agreement could potentially limit Mr. Vizirgianakis's ability to act in the best interests of the company if a significant opportunity arises.
• There is a risk that the new chairman's vision may not align with the company's existing strategy.

Future Outlook

The company aims to continue its growth trajectory under the new leadership, with a focus on the potential of its Helium Plasma Technology in the cosmetic surgery market.

Management Comments

• Charlie Goodwin, President and Chief Executive Officer, expressed gratitude to Andrew Makrides for his contributions and welcomed Stavros Vizirgianakis to the Chairman role.
• Andrew Makrides stated it was a privilege to serve Apyx Medical and believes the company is well-positioned for future success.
• Stavros Vizirgianakis expressed his honor in being named Chairman and his belief in the potential of the company's technology.

Industry Context

The appointment of a new chairman with extensive experience in the medical device industry aligns with the company's focus on growth and innovation in the advanced energy technology sector. This change is part of a broader trend of leadership transitions in the medical device industry.

Comparison to Industry Standards

• The appointment of a new chairman with a strong background in medical devices is a common practice in the industry to bring fresh perspectives and expertise.
• The standstill agreement is a standard measure to ensure stability during leadership transitions.
• The process of identifying an additional independent director is consistent with corporate governance best practices.
• The compensation and benefits provided to the new chairman are in line with industry standards for non-employee directors.

Management Changes

Stakeholder Impact

• Shareholders may view the leadership transition positively due to the new chairman's experience.
• Employees may experience a change in leadership style and strategic direction.
• Customers and suppliers may not be directly impacted by this change.

Next Steps

• The company will nominate Mr. Vizirgianakis for reelection at the 2024 Annual Meeting of Stockholders.
• The company and Mr. Vizirgianakis will cooperate to identify a mutually acceptable additional director within six to nine months.
• The company will hold the 2024 Annual Meeting no later than August 31, 2024.

Key Dates

Keywords

Board of Directors, Chairman, Stavros Vizirgianakis, Andrew Makrides, Medical Device, Corporate Governance, Standstill Agreement, Director Appointment